Related Experiment Videos
High-sensitivity hybridization assay for quantitation of residual E. coli DNA
Xiaoying Ji1, Kwan Lee, Byron DiPaolo
1GlaxoSmithKline, King of Prussia, PA 19406, USA. shelley_ji-1@sbphrd.com
Abstract:
Impurity assays for recombinant protein therapeutics are essential to ensure batch-to-batch consistency and to meet the FDA's criteria for a well-characterized biopharmaceutical. For determination of residual host cell DNA, membrane hybridization assays utilizing radiolabeled DNA probes prepared from the host cell's genomic DNA have traditionally been used for products derivedfrom bacterial expression systems to obtain the required low picogram sensitivity. Nonradioactive methods, while desirable to eliminate radioactive waste disposal and safety issues, typically suffer from poor sensitivity and high backgrounds. We report the development of a suitably sensitive, nonradioactive assay to quantitate residual E. coli DNA levels in purified protein drugs by means of a slot-blot hybridization method. The assay utilizes digoxigenin-labeled E. coli DNA probes and SuperSignal chemiluminescent substrate. The optimized chemiluminescent hybridization assay has both low background and high sensitivity, allowing routine detection of 2.5 pg E. coli DNA. The method can be tailored for detection/quantitation of DNA contamination in recombinant protein products expressed in E. coli or other bacterial expression systems.
Insights
A new nonradioactive assay accurately detects residual E. coli DNA in protein drugs. This method offers high sensitivity and low background, ensuring biopharmaceutical safety and consistency.
Area of Science:
- Biotechnology
- Analytical Chemistry
- Pharmaceutical Science
Background:
- Recombinant protein therapeutics require rigorous impurity assays for FDA compliance.
- Traditional radiolabeled DNA probes for host cell DNA detection pose safety and disposal challenges.
- Existing nonradioactive methods often lack the sensitivity needed for residual DNA quantitation.
Purpose of the Study:
- To develop a sensitive, nonradioactive assay for quantifying residual E. coli DNA in purified protein drugs.
- To provide a safer and more efficient alternative to radioactive hybridization assays.
- To ensure batch-to-batch consistency and characterization of biopharmaceuticals.
Main Methods:
- Development of a slot-blot hybridization assay.
- Utilization of digoxigenin-labeled E. coli DNA probes.
- Employing SuperSignal chemiluminescent substrate for detection.
Main Results:
- The optimized assay demonstrates high sensitivity with a low background.
- Routine detection of as little as 2.5 pg of E. coli DNA is achievable.
- The method is suitable for various bacterial expression systems.
Conclusions:
- A robust, nonradioactive assay for residual E. coli DNA quantitation has been established.
- This assay meets the sensitivity requirements for biopharmaceutical quality control.
- The method offers a practical alternative to radioactive assays for DNA impurity analysis.